Author | Jacob Sands, MD | OncLive

Author | Jacob Sands, MD


Dr. Sands on the FDA Approval of Lurbinectedin in Small Cell Lung Cancer

June 19, 2020


Jacob Sands, MD, discusses the FDA approval of lurbinectedin for the treatment of adult patients with metastatic small cell lung cancer with disease progression, following platinum-based chemotherapy.

Dr. Sands on the Rationale to Explore DS-1062 in Advanced NSCLC

June 20, 2019


Jacob Sands, MD, physician, Dana-Farber Cancer Institute, instructor in medicine, Harvard Medical School, discusses the rationale to explore DS-1062 in advanced non–small cell lung cancer (NSCLC).